Publication:
Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain

dc.contributor.authorRyan, Pablo
dc.contributor.authorValencia, Jorge
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorTorres-Macho, Juan
dc.contributor.authorTroya, Jesús
dc.contributor.authorPueyo, Ángel
dc.contributor.authorMuñoz-Gómez, María José
dc.contributor.authorMuñoz-Rivas, Nuria
dc.contributor.authorVázquez-Morón, Sonia
dc.contributor.authorMartinez, Isidoro
dc.contributor.authorLazarus, Jeffrey V
dc.contributor.authorResino, Salvador
dc.contributor.funderGilead Sciences (Spain)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderAbbVie
dc.contributor.funderAsociación Española para Estudio del Higado (AEEH)es_ES
dc.contributor.funderMadrid Positivo Associationes_ES
dc.date.accessioned2024-05-22T08:42:58Z
dc.date.available2024-05-22T08:42:58Z
dc.date.issued2021-10
dc.description.abstractBackground: The burden of hepatitis C virus (HCV) infection among marginalized people in Spain is high, despite the fact that HCV prevalence has decreased in recent years. We aimed to assess the effectiveness of a simplified point-of-care (PoC) model for screening for active HCV infection via a mobile unit and subsequent linkage to care with the assistance of navigators. Methods: We carried out a prospective study on 2001 participants from Madrid, Spain. A nurse and a navigator/educator screened for hepatitis C in a mobile unit, using the OraQuick HCV Rapid Antibody Test and Xpert HCV VL Fingerstick assay. Participants with active HCV were referred to the hospital the same day with a navigator for evaluation and treatment of HCV. Results: Overall, 1621 (81%) participants had not been exposed to HCV, 380 (18.9%) were positive for HCV antibodies, and 136 (6.8%) had active hepatitis C. Among the latter, 134 (98.5%) received the HCV screening results, 133 (97.8%) had an appointment at the hospital, 126 (92.8%) were seen by a physician once they were at the hospital, and 105 (77.2%) started HCV treatment. Being over 50 years old and a person who uses drugs, particularly people who inject drugs (PWID), was directly associated with active hepatitis C (p<0.05). PWID were the only patients with HCV reinfection (4.3% in people without recent injecting drug use and 5.9% in people with recent injecting drug use). Among PWID, no income and daily alcohol intake were also directly associated with active hepatitis C. People with recent injecting drug use showed the lowest rates of attendance at the hospital (91.8%) and starting HCV treatment (70.4%). Conclusion: HCV screening using a two-step PoC-based strategy and its linkage to care was extremely efficient for identifying and treating marginalized people with active hepatitis C, thanks to the use of a mobile unit with personnel and technical equipment, an interdisciplinary team, and collaboration between institutions.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was funded by a research grant from Gilead Science (IN-ES-987-5391 and GLD20_0144) and Instituto de Salud Carlos III (ISCII; grant numbers PI20CIII/00004 and RD16CIII/0002/0002 to SR). It also received funding from AbbVie, Asociación Española para Estudio del Higado (AEEH), and Madrid Positivo Association.es_ES
dc.format.page103424es_ES
dc.format.volume96es_ES
dc.identifier.citationInt J Drug Policy. 2021 Oct:96:103424.es_ES
dc.identifier.doi10.1016/j.drugpo.2021.103424es_ES
dc.identifier.e-issn1873-4758es_ES
dc.identifier.journalThe International journal on drug policyes_ES
dc.identifier.pubmedID34429222es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19518
dc.language.isoenges_ES
dc.publisherElsevier
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.drugpo.2021.103424es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHepatitis Ces_ES
dc.subjectScreening mobile unites_ES
dc.subjectPeople who use drugses_ES
dc.subjectPoint-of-carees_ES
dc.subjectLinkage-to-carees_ES
dc.subjectHCV testinges_ES
dc.subjectHCV treatmentes_ES
dc.subjectSpaines_ES
dc.subject.meshHepatitis Ces_ES
dc.subject.meshSubstance Abuse, Intravenouses_ES
dc.subject.meshAntiviral Agentses_ES
dc.subject.meshHepaciviruses_ES
dc.subject.meshHepatitis C Antibodieses_ES
dc.subject.meshHumanses_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshProspective Studieses_ES
dc.subject.meshSpaines_ES
dc.titleDetection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spaines_ES
dc.typeresearch articlees_ES
dc.type.hasVersionSMURes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication0a5ce675-0dc5-483a-b8be-b573f3757285
relation.isAuthorOfPublication67f2bc43-2edd-4446-a434-c8145a43f451
relation.isAuthorOfPublication91fafbb0-4d25-4be8-969e-5b9941af71ca
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication.latestForDiscovery0a5ce675-0dc5-483a-b8be-b573f3757285
relation.isFunderOfPublicatione30731f7-32c2-43af-b658-fe28964bc958
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationffb8e2d3-a3e4-4345-ade9-736e37d36399
relation.isFunderOfPublication.latestForDiscoverye30731f7-32c2-43af-b658-fe28964bc958
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
DetectionActiveHepatitis_C_2021.pdf
Size:
2.19 MB
Format:
Adobe Portable Document Format
Description: